PMID- 26137003
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201001
IS  - 1792-1074 (Print)
IS  - 1792-1082 (Electronic)
IS  - 1792-1074 (Linking)
VI  - 9
IP  - 5
DP  - 2015 May
TI  - Effect of combined 5-aza-2'deoxycytidine and cisplatin treatment on the P15 lung 
      adenocarcinoma cell line.
PG  - 2007-2012
AB  - Aberrant promoter hypermethylation resulting in the epigenetic silencing of 
      apoptosis-associated genes is a key process in the chemotherapeutic treatment of 
      cancer. The nucleoside analog, 5-aza-2'deoxycytidine (DAC), inhibits the activity 
      of DNA methyltransferase enzymes and is able to restore the expression levels of 
      genes that have been silenced by aberrant DNA methylation. The aim of the present 
      study was to investigate the effect of combined treatment with DAC and cisplatin 
      (CDDP) on the lung adenocarcinoma cell line, P15. Growth inhibition was examined 
      using a clone formation assay and growth inhibitory activities by cell counting 
      during treatment with DAC alone, CDDP alone or DAC followed by CDDP. In addition, 
      changes in the mRNA expression levels of various apoptosis-associated genes 
      following treatment with increasing concentrations of DAC were determined using 
      reverse transcription-polymerase chain reaction. Furthermore, terminal 
      deoxynucleotidyl transferase-mediated dUTP nick end labeling (TUNEL) analysis was 
      used to detect the number of apoptotic P15 tumor cells following treatment with 
      DAC and/or CDDP. The results indicated that DAC treatment alone restored the mRNA 
      expression levels of p73, p16(INK4a) , B-cell lymphoma (Bcl)-2-associated agonist 
      of cell death and Bcl-2-associated X protein. In addition, combined therapy with 
      DAC and CDDP was found to significantly suppress the growth of P15 tumor cells 
      compared with DAC or CDDP treatment alone. In conclusion, DAC may enhance the 
      chemosensitivity of the P15 cell line to treatment with CDDP.
FAU - Liu, Kaishan
AU  - Liu K
AD  - Department of Pathology, School of Medicine, Jinan University, Guangzhou, 
      Guangdong 510632, P.R. China.
FAU - Huang, Wenyan
AU  - Huang W
AD  - Department of Pathology, School of Medicine, Jinan University, Guangzhou, 
      Guangdong 510632, P.R. China.
FAU - Gao, Weisong
AU  - Gao W
AD  - Department of Pathology, School of Medicine, Jinan University, Guangzhou, 
      Guangdong 510632, P.R. China.
FAU - He, Wenfang
AU  - He W
AD  - Department of Pathology, School of Medicine, Jinan University, Guangzhou, 
      Guangdong 510632, P.R. China.
LA  - eng
PT  - Journal Article
DEP - 20150226
PL  - Greece
TA  - Oncol Lett
JT  - Oncology letters
JID - 101531236
PMC - PMC4467288
OTO - NOTNLM
OT  - 5-aza-2'deoxycytidine
OT  - apoptosis
OT  - chemosensitivity
OT  - cisplatin
OT  - methylation
EDAT- 2015/07/03 06:00
MHDA- 2015/07/03 06:01
PMCR- 2015/02/26
CRDT- 2015/07/03 06:00
PHST- 2014/05/15 00:00 [received]
PHST- 2015/02/10 00:00 [accepted]
PHST- 2015/07/03 06:00 [entrez]
PHST- 2015/07/03 06:00 [pubmed]
PHST- 2015/07/03 06:01 [medline]
PHST- 2015/02/26 00:00 [pmc-release]
AID - OL-0-0-2986 [pii]
AID - 10.3892/ol.2015.2986 [doi]
PST - ppublish
SO  - Oncol Lett. 2015 May;9(5):2007-2012. doi: 10.3892/ol.2015.2986. Epub 2015 Feb 26.